Skip to main content

Recursion Pharmaceuticals, Inc. (RXRX)

NASDAQ: RXRX · IEX Real-Time Price · USD
18.79 0.53 (2.90%)
Oct 26, 2021 2:50 PM EDT - Market open
Market Cap3.07B
Revenue (ttm)8.83M
Net Income (ttm)n/a
Shares Out138.36M
EPS (ttm)-2.40
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,468,534
Open18.35
Previous Close18.26
Day's Range17.80 - 19.29
52-Week Range16.50 - 42.81
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About RXRX

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company...

IndustryBiotechnology
IPO DateApr 16, 2021
Employees270
Stock ExchangeNASDAQ
Ticker SymbolRXRX
Full Company Profile

Financial Performance

In 2020, RXRX's revenue was $3.96 million, an increase of 70.85% compared to the previous year's $2.32 million. Losses were -$87.01 million, 40.6% more than in 2019.

Financial Statements

News

Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas

SALT LAKE CITY, Oct. 7, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automat...

2 weeks ago - PRNewsWire

BioHive Names Katelin Roberts Executive Director

SALT LAKE CITY--(BUSINESS WIRE)--BioHive, with a mission to brand, build and bring together Utah's robust and growing life sciences industry, names Katelin Roberts Executive Director.

3 weeks ago - Business Wire

Recursion is Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis

SALT LAKE CITY, Sept. 29, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, autom...

3 weeks ago - PRNewsWire

Recursion Reports Second Quarter 2021 Financials and Provides Business Updates

SALT LAKE CITY, Aug. 13, 2021 /PRNewswire/ -- Recursion (Nasdaq: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automa...

2 months ago - PRNewsWire

Recursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhD

SALT LAKE CITY, July 13, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automa...

3 months ago - PRNewsWire

Recursion Opens Child Care Center to Support Employees

SALT LAKE CITY, July 12, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automa...

3 months ago - PRNewsWire

Recursion Signs Lease With Vestar for an Additional 100,000 sf of Space at the Gateway in Downtown Salt Lake City

SALT LAKE CITY, July 1, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automat...

3 months ago - PRNewsWire

Got $2,500? Check Out These 2 Biotech 2.0 Stocks

They're poised to disrupt the drug development process.

Other symbols:ME
3 months ago - The Motley Fool

Recursion Announces Multi-Year Collaboration with Mila for Tech-Enabled Drug Discovery

Recursion to open office space within Mila and build machine learning team to focus on some of drug discovery's most challenging problems MONTRÉAL, June 23, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX)...

4 months ago - PRNewsWire

Recursion Announces its First Major Multidisciplinary Expansion, in Toronto, to Further Tech-Enabled Drug Discovery

The company aims to hire up to 50 people by the end of 2021 across disciplines of data science, machine learning, engineering, product management and computational biology. TORONTO, June 15, 2021 /PRNew...

4 months ago - PRNewsWire

Losers Outnumber Gainers in Biotech IPOs This Year

Is investor enthusiasm for new biotechnology companies waning? Based on the performance of the 35 biotechs that went public in the first quarter, that may be the case.

Other symbols:DBTXEWTXTAK
4 months ago - GuruFocus

Recursion Announces First Internally-Developed NCE Advanced to IND-Enabling Studies to Potentially Treat Clostridium ...

SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biol...

5 months ago - PRNewsWire

Recursion Reports First Quarter 2021 Financials and Provides Business Updates

SALT LAKE CITY, May 12, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biol...

5 months ago - PRNewsWire

2 Hot Biotech IPOs to Consider

These companies are already making great strides where few dare to tread.

Other symbols:BMEA
5 months ago - The Motley Fool

Recursion Pharmaceuticals Announces Closing of Initial Public Offering

SALT LAKE CITY, April 21, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we")  announced the closing on April 20, 2021 of its initial public offering of 27,878,787 shares of its C...

6 months ago - PRNewsWire

Recursion Pharmaceuticals Announces Pricing of Initial Public Offering

Recursion Pharmaceuticals, Inc. ("Recursion" or "we") today announced the pricing of its initial public offering of its Class A common stock at...

6 months ago - PRNewswire

At $306 Million, Recursion Pharmaceuticals’ IPO will be Bigger than Expected

After initially indicating it intended to raise $100 million in its Nasdaq debut, the Salt Lake City-based company will now look at bringing in approximately $306 million.

6 months ago - BioSpace

AI drug discovery biotech Recursion Pharmaceuticals files for a $100 million IPO

Recursion Pharmaceuticals, a Phase 2-ready biotech using machine learning to develop therapies for various indications, filed on Monday with the SEC to raise up to $100 million in an initial public offe...

7 months ago - NASDAQ

Recursion Pharmaceuticals IPO Registration Document (S-1)

Recursion Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

7 months ago - SEC